High-mobility group box 1 (HMGB1) exhibits various functions according to its subcellular location, which is finely conditioned by diverse post-translational modifications, such as acetylation. The nuclear HMGB1 may prevent from cardiac hypertrophy, whereas its exogenous protein is proven to induce hypertrophic response. This present study sought to investigate the regulatory relationships between poly(ADP-ribose) polymerase 1 (PARP1) and HMGB1 in the process of pathological myocardial hypertrophy. Primary-cultured neonatal rat cardiomyocytes (NRCMs) were respectively incubated with three cardiac hypertrophic stimulants, including angiotensin II (Ang II), phenylephrine (PE), and isoproterenol (ISO), and cell surface area and the mRNA expression of hypertrophic biomarkers were measured. the catalytic activity of PARP1 was remarkably enhanced, meanwhile HMGB1 excluded from the nucleus. PARP1 overexpression by infecting with adenovirus PARP1 (Ad-PARP1) promoted the nuclear export of HMGB1, facilitated its secretion outside the cell, aggravated cardiomyocyte hypertrophy, which could be alleviated by HMGB1 overexpression. PE treatment led to the similar results, while that effect was widely depressed by PARP1 silencing or its specific inhibitor AG14361. Moreover, SD rats were intraperitoneally injected with 3-aminobenzamide (3AB, 20 mg/kg every day, a well-established PARP1 inhibitor) 7 days after abdominal aortic constriction (AAC) surgery for 6 weeks, echocardiography and morphometry of the hearts were measured. Pre-treatment of 3AB relieved AAC-caused the translocation of nuclear HMGB1 protein, cardiac hypertrophy, and heart dysfunction. Our research offers a novel evidence that PARP1 combines with HMGB1 and accelerates its translocation from nucleus to cytoplasm, and the course finally causes cardiac hypertrophy.
Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $57.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Yu SS, Cai Y, Ye JT, Pi RB, Chen SR, Liu PQ, et al. Sirtuin 6 protects cardiomyocytes from hypertrophy in vitro via inhibition of NF-κB-dependent transcriptional activity. Br J Pharmacol. 2013;168:117–28.
Frey N, Katus HA, Olson EN, Hill JA. Hypertrophy of the heart: a new therapeutic target. Circulation. 2004;109:1580–9.
Glennon PE, Sugden PH, Poole-Wilson PA. Cellular mechanisms of cardiac hypertrophy. Br Heart J. 1995;73:496–9.
Funayama A, Shishido T, Netsu S, Narumi T, Kadowaki S, Takahashi H, et al. Cardiac nuclear high mobility group box 1 prevents the development of cardiac hypertrophy and heart failure. Cardiovasc Res. 2013;99:657–64.
Srinivasan M, Banerjee S, Palmer A, Zheng G, Chen A, Bosland MC, et al. HMGB1 in hormone-related cancer: a potential therapeutic target. Horm Cancer. 2014;5:127–39.
Jia ZK, Xue R, Liu GQ, Li L, Yang JJ, Pi GF, et al. HMGB1 is involved in the protective effect of the PPARα agonist fenofibrate against cardiac hypertrophy. PPAR Res. 2014;2014:541394.
Li YF, Li XH, Qu Y, Huang JC, Zhu TT, Zhao FY, et al. Role of HMGB1 translocation to neuronal nucleus in rat model with septic brain injury. Neurosci Lett. 2017;645:90–6.
Takahashi K, Fukushima S, Yamahara K, Yashiro K, Shintani Y, Coppen SR, et al. Modulated inflammation by injection of high-mobility group box 1 recovers post-Infarction chronically failing heart. Circulation. 2008;118:S106–114.
Kohno T, Anzai T, Naito K, Miyasho T, Okamoto M, Yokota H, et al. Role of high-mobility group box 1 protein in post-infarction healing process and left ventricular remodelling. Cardiovasc Res. 2009;81:565–73.
Tang YT, Zhao X, Daniel A, Xiao XZ, Wang HC, Ulf A, et al. Regulation of posttranslational modifications of HMGB1 during immune responses. Antioxid Redox Sign. 2016;24:620–34.
Zhang L, Liu M, Jiang H, Yu Y, Yu P, Tong R, et al. Extracellular high-mobility group box 1 mediates pressure overload-induced cardiac hypertrophy and heart failure. J Cell Mol Med. 2016;20:459–70.
Su FF, Shi MQ, Guo WG, Liu XT, Wang HT, Lu ZF, et al. High-mobility group box 1 induces calcineurin-mediated cell hypertrophy in neonatal rat ventricular myocytes. Mediat Inflamm. 2012;2012:805149.
Wacker DA, Frizzell KM, Zhang T, Kraus WL. Regulation of chromatin structure and chromatin-dependent transcription by poly(ADP-ribose) polymerase-1: possible targets for drug-based therapies. Subcell Biochem. 2007;41:45–69.
Wacker DA, Ruhl DD, Balagamwala EH, Hope KM, Zhang T, Kraus WL. The DNA binding and catalytic domains of poly(ADP-Ribose) polymerase 1 cooperate in the regulation of chromatin structure and transcription. Mol Cell Biol. 2007;27:7475–85.
Krishnakumar R, Kraus WL. PARP-1 regulates chromatin structure and transcription through a KDM5B-dependent pathway. Mol Cell. 2010;39:736–49.
Gerace E, Masi A, Resta F, Felici R, Landucci E, Mello T, et al. PARP-1 activation causes neuronal death in the hippocampal CA1 region by increasing the expression of Ca2+-permeable AMPA receptors. Neurobiol Dis. 2014;70:43–52.
Kanai M, Hanashiro K, Kim SH, Hanai S, Boulares AH, Miwa M, et al. Inhibition of Crm1-p53 interaction and nuclear export of p53 by poly(ADP-ribosyl)ation. Nat Cell Biol. 2007;9:1175–83.
Olabisi OA, Soto-Nieves N, Nieves E, Yang TT, Yang X, Yu RY, et al. Regulation of transcription factor NFAT by ADP-ribosylation. Mol Cell Biol. 2008;28:2860–71.
Lönn P, van der Heide LP, Dahl M, Hellman U, Heldin CH, Moustakas A. PARP-1 attenuates Smad-mediated transcription. Mol Cell. 2010;40:521–32.
Sakamaki J, Daitoku H, Yoshimochi K, Miwa M, Fukamizu A. Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1. Biochem Bioph Res Commun. 2009;382:497–502.
Luo X, Nie J, Wang S, Chen Z, Chen W, Li D, et al. Poly(ADP-ribosyl) ation of FOXP3 protein mediated by PARP-1 protein regulates the function of regulatory T cells. J Biol Chem. 2015;290:28675–82.
Ju BG, Solum D, Song EJ, Lee KJ, Rose DW, Glass CK, et al. Activating the PARP-1 sensor component of the groucho/TLE1 corepressor complex mediates a CaMKinase IIdelta-dependent neurogenic gene activation pathway. Cell. 2004;119:815–29.
Pillai JB, Gupta M, Rajamohan SB, Lang R, Raman J, Gupta MP. Poly(ADP-ribose) polymerase-1-deficient mice are protected from angiotensin II-induced cardiac hypertrophy. Am J Physiol Heart Circ Physiol. 2006;291:H1545–H1553.
Feng GS, Zhu CG, Li ZM, Wang PX, Huang Y, Liu M, et al. Synthesis of the novel PARP-1 inhibitor AG-690/11026014 and its protective effects on angiotensin II-induced mouse cardiac remodeling. Acta Pharmacol Sin. 2017;38:638–50.
Lu J, Zhang RW, Hong HQ, Yang ZL, Sun DP, Sun SY, et al. The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy. Biochim Biophys Acta. 2016;1863:3027–39.
Ditsworth D, Zong WX, Thompson CB. Activation of poly(ADP)-ribose polymerase (PARP-1) induces release of the pro-inflammatory mediator HMGB1 from the nucleus. J Biol Chem. 2007;282:17845–54.
Lu J, Sun DP, Liu ZP, Li M, Hong HQ, Liu C, et al. SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. Transl Res. 2016;172:96–112.e6.
Yue ZB, Ma YZ, You J, Li ZM, Ding YQ, He P, et al. NMNAT3 is involved in the protective effect of SIRT3 in Ang II-induced cardiachypertrophy. Exp Cell Res. 2016;347:261–73.
Shen PY, Feng XJ, Zhang XY, Huang XY, Liu SL, Lu X, et al. SIRT6 suppresses phenylephrine-induced cardiomyocyte hypertrophy though inhibiting p300. J Pharmacol Sci. 2016;132:31–40.
Sun SY, Hu YH, Zheng QY, Guo Z, Sun DP, Chen SR, et al. PARP1 induces cardiac fibrosis by mediating mTOR activity. J Cell Biochem. 2017. https://doi.org/10.1002/jcb.26649.
Gravning J, Ahmed MS, von Lueder TG, Edvardsen T, Attramadal H. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressure-overload. Int J Cardiol. 2013;168:2049–56.
Zhang XY, Li W, Shen PY, Feng XJ, Yue ZB, Lu J, et al. STAT3 suppression is involved in the protective effect of SIRT6 against cardiomyocyte hypertrophy. J Cardiovasc Pharmacol. 2016;68:204–14.
Feng XJ, Gao H, Gao S, Li ZM, Li H, Lu J, et al. The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1. Br J Pharmacol. 2015;172:2852–63.
Putinski C, Abdul-Ghani M, Stiles R, Brunette S, Dick SA, Fernando P, et al. Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013;110:E4079–4087.
Wu CX, He LX, Guo H, Tian XX, Liu Q, Sun H. Inhibition effect of glycyrrhizen in lipopolysaccharide-induced high-mobility group box 1 releasing and expression from RAW264.7 cells. Shock. 2015;43:412–21.
Yang ZY, Li L, Chen LJ, Yuan WW, Dong LM, Zhang YS, et al. PARP-1 mediates LPS-induced HMGB1 release by macrophages through regulation of HMGB1 acetylation. J Immunol. 2014;193:6114–23.
Venereau E, De Leo F, Mezzapelle R, Careccia G, Musco G, Bianchi ME. HMGB1 as biomarker and drug target. Pharmacol Res. 2016;111:534–44.
Ren J, Xu XH, Wang QR, Ren SY, Dong ML, Zhang YM. Permissive role of AMPK and autophagy in adiponectin deficiency-accentuated myocardial injury and inflammation in endotoxemia. J Mol Cell Cardiol. 2016;93:18–31.
Lei YH, Li X, Yuan F, Liu L, Zhang J, Yang YP, et al. Toll-like receptor 4 ablation rescues against paraquat-triggered myocardial dysfunction: role of ER stress and apoptosis. Environ Toxicol. 2017;32:656–68.
Yu C, Kim BS, Kim E. FAF1 mediates regulated necrosis through PARP1 activation upon oxidative stress leading to dopaminergic neurodegeneration. Cell Death Differ. 2016;23:1873–85.
Andrabi SA, Umanah GK, Chang C, Stevens DA, Karuppagounder SS, Gagné JP, et al. Poly (ADP-ribose) polymerase-dependent energy depletion occurs through inhibition of glycolysis. Proc Natl Acad Sci U S A. 2014;111:10209–14.
Bartha E, Solti I, Kereskai L, Lantos J, Plozer E, Magyar K, et al. PARP inhibition delays transition of hypertensive cardiopathy to heart failure in spontaneously hypertensive rats. Cardiovasc Res. 2009;83:501–10.
Yang MH, Liu LY, Xie M, Sun XF, Yu Y, Kang R, et al. Poly-ADP-ribosylation of HMGB1 regulates TNFSF10/TRAIL resistance through autophagy. Autophagy. 2015;11:214–24.
This research was supported by grants from the 111 Project (No. B16047 to Pei-qing LIU), National Natural Science Foundation of China (81473205, 81673433 to Pei-qing LIU), Major Project of Platform Construction Education Department of Guangdong Province (No. 2014GKPT002 to Pei-qing LIU), and Special Program for Applied Science and Technology of Guangdong Province (No. 2015B020232009, 2014B020210003 and 2013B090700010 to Pei-qing LIU), National Engineering and Technology Research Center for New Drug Druggability Evaluation (Seed Program of Guangdong Province), Guangzhou Science and Technology Program Project (No. 201604020121 to Pei-qing LIU), Medical Scientific Research Foundation of Guangdong Province (No. A2018078 to Jing LU).
Zhuo-ming LI and Pei-qing LIU designed the study. Qian LI, Shu-ya SUN, Lu-ping WANG, and Zhen GUO performed the experiments. Qian LI, Pan-xia WANG, and Han-wei YANG analyzed the data. Qian LI, Jing LU, and Jian-tao YE wrote the manuscript.